Live News EQUITY L impact Jul 01, 2026, 11:48 AM UTC

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ: AKBA ) with a Buy and maintains $6 price target.

SQUAWKNEWS Updated Jul 01, 2026, 11:48 AM UTC

HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ: AKBA ) with a Buy and maintains $6 price target.